Literature DB >> 31767627

The NOTCH-FOXM1 Axis Plays a Key Role in Mitochondrial Biogenesis in the Induction of Human Stem Cell Memory-like CAR-T Cells.

Taisuke Kondo1, Makoto Ando2, Nao Nagai2, Wataru Tomisato3, Tanakorn Srirat2, Binbin Liu2, Setsuko Mise-Omata2, Mari Ikeda2, Shunsuke Chikuma2, Hiroshi Nishimasu4, Osamu Nureki4, Mitsuyo Ohmura5, Noriyo Hayakawa5, Takako Hishiki5, Ryosuke Uchibori6, Keiya Ozawa6,7, Akihiko Yoshimura1.   

Abstract

Recent studies have shown that stem cell memory T (TSCM) cell-like properties are important for successful adoptive immunotherapy by the chimeric antigen receptor-engineered-T (CAR-T) cells. We previously reported that both human and murine-activated T cells are converted into stem cell memory-like T (iTSCM) cells by coculture with stromal OP9 cells expressing the NOTCH ligand. However, the mechanism of NOTCH-mediated iTSCM reprogramming remains to be elucidated. Here, we report that the NOTCH/OP9 system efficiently converted conventional human CAR-T cells into TSCM-like CAR-T, "CAR-iTSCM" cells, and that mitochondrial metabolic reprogramming played a key role in this conversion. NOTCH signaling promoted mitochondrial biogenesis and fatty acid synthesis during iTSCM formation, which are essential for the properties of iTSCM cells. Forkhead box M1 (FOXM1) was identified as a downstream target of NOTCH, which was responsible for these metabolic changes and the subsequent iTSCM differentiation. Like NOTCH-induced CAR-iTSCM cells, FOXM1-induced CAR-iTSCM cells possessed superior antitumor potential compared with conventional CAR-T cells. We propose that NOTCH- or FOXM1-driven CAR-iTSCM formation is an effective strategy for improving cancer immunotherapy. SIGNIFICANCE: Manipulation of signaling and metabolic pathways important for directing production of stem cell memory-like T cells may enable development of improved CAR-T cells. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31767627     DOI: 10.1158/0008-5472.CAN-19-1196

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  CD19-targeted CAR regulatory T cells suppress B cell pathology without GvHD.

Authors:  Yuki Imura; Makoto Ando; Taisuke Kondo; Minako Ito; Akihiko Yoshimura
Journal:  JCI Insight       Date:  2020-07-23

Review 2.  Signaling from T cell receptors (TCRs) and chimeric antigen receptors (CARs) on T cells.

Authors:  Ling Wu; Qianru Wei; Joanna Brzostek; Nicholas R J Gascoigne
Journal:  Cell Mol Immunol       Date:  2020-05-25       Impact factor: 11.530

3.  Combined overexpression of four transcription factors promotes effector T cell dedifferentiation toward early phenotypes.

Authors:  Lijun Yan; Yusheng Ou; Shengfang Xia; Jianqing Huang; Wenfeng Zhang; Hongwei Shao; Han Shen; Huaben Bo; Changli Tao; Jinquan Wang; Fenglin Wu
Journal:  Immunogenetics       Date:  2022-01-10       Impact factor: 2.846

4.  USP39 facilitates breast cancer cell proliferation through stabilization of FOXM1.

Authors:  Zhenwang Zhang; Wu Liu; Xiajun Bao; Tian Sun; Jiawei Wang; Mengxi Li; Chao Liu
Journal:  Am J Cancer Res       Date:  2022-08-15       Impact factor: 5.942

Review 5.  Cellular networks controlling T cell persistence in adoptive cell therapy.

Authors:  Jack D Chan; Junyun Lai; Clare Y Slaney; Axel Kallies; Paul A Beavis; Phillip K Darcy
Journal:  Nat Rev Immunol       Date:  2021-04-20       Impact factor: 53.106

Review 6.  Manipulating the Metabolism to Improve the Efficacy of CAR T-Cell Immunotherapy.

Authors:  Marsha Pellegrino; Francesca Del Bufalo; Biagio De Angelis; Concetta Quintarelli; Ignazio Caruana; Emmanuel de Billy
Journal:  Cells       Date:  2020-12-24       Impact factor: 6.600

Review 7.  Vascular Notch Signaling in Stress Hematopoiesis.

Authors:  Can Huang; Dawei Yang; George W Ye; Charles A Powell; Peipei Guo
Journal:  Front Cell Dev Biol       Date:  2021-01-21

8.  Tissue-resident memory T cells in tumor immunity and immunotherapy.

Authors:  Karolina Okła; Donna L Farber; Weiping Zou
Journal:  J Exp Med       Date:  2021-04-05       Impact factor: 14.307

Review 9.  Optimizing the Clinical Impact of CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia: Looking Back While Moving Forward.

Authors:  Pouya Safarzadeh Kozani; Pooria Safarzadeh Kozani; Fatemeh Rahbarizadeh
Journal:  Front Immunol       Date:  2021-10-28       Impact factor: 7.561

Review 10.  Optimization of metabolism to improve efficacy during CAR-T cell manufacturing.

Authors:  Meng Zhang; Xin Jin; Rui Sun; Xia Xiong; Jiaxi Wang; Danni Xie; MingFeng Zhao
Journal:  J Transl Med       Date:  2021-12-07       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.